Adhesion therapeutique aux antiagregants chez le patient coronarien.

Aspirin/therapeutic use; Coronary Artery Disease/drug therapy; Humans; Medication Adherence/statistics & numerical data; Platelet Aggregation Inhibitors/therapeutic use; Ticlopidine/analogs & derivatives/therapeutic use

Abstract :

[en] Clinical benefit of antiplatelet therapy is established for cardiovascular disease and percutaneous coronary intervention (PCI). Dual antiplatelet therapy is used to optimize platelet inhibition. However, cardiovascular events still occur. Aspirin/clopidogrel resistance and poor compliance are the main factors implied in recurrent events. Compliance to dual antiplatelet therapy is particularly relevant during the first 6 months following acute coronary syndromes and PCI. Furthermore, several studies have shown association between antiplatelet resistance and poor compliance. Additionally, late (1 month to 1 year) and very late (> 1 year) stent thromboses are intimately linked to interruption of antiplatelet treatment. In this article we review the latest data about compliance, resistance and recommendations regarding antiplatelet therapy.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Legrand, D.

Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie

Language :

French

Title :

Adhesion therapeutique aux antiagregants chez le patient coronarien.

Alternative titles :

[en] Adherence to antiplatelet therapy in patients with coronary artery disease

Publication date :

2010

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6

Pages :

304-10

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 May 2014

Statistics

Number of views

270 (0 by ULiège)

Number of downloads

433 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Antithrobotic Trialist Collaboration. - Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ, 2002, 324, 71-86.
Legrand DA, Scheen AJ. - L'aspirine en prévention primaire des maladies cardiovasculaires chez le patient diabétique. Rev Med Liege, 2007, 62, 610-615.
Legrand DA, Scheen AJ. - La résistance à l'aspirine chez le patient diabétique : découverte de laboratoire ou réalité clinique. Rev Med Liege, 2006, 10, 682-690.
Schwartz KA, Schwartz DE, Ghosheh K, et al. - Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol, 2005, 95, 973-975. (Pubitemid 40487749)
Ho P, Peterson E, Wang L, et al. - Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA, 2008, 299, 532-539. (Pubitemid 351222546)
Von Pape KW, Strupp G, Bonzel T, Bohner J. - Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost, 2005, 94, 889-891. (Pubitemid 41489258)
Cotter G, Shemesh E, Zehavi M, et al. - Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J, 2004, 147, 293-300.
Komiya T, Kudo M, Urabe T, Mizuno Y. - Compliance with antiplatelet therapy in patient with ischemic cerebrovascular disease. Stroke, 1994, 25, 2337-2347.
Schwartz KA, Schwartz DE, Barber K, et al. - Minimal frequency of aspirin resistance after observed aspirin ingestion. Blood, 2005, 106, 164.
Cuisset T, Frere C, Quiliti J, et al. - Aspirin non compliance is the major cause of aspirin resistance in patient undergoing coronary stenting. Am Heart J, 2009, 157, 889-893.
Serebruany V, Cherala G, Craig W, et al. - Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of resistance. Am Heart J, 2009, 158, 925-932.
Bowry AD, Brookhart MA, Choudhry NK. - Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol, 2008, 101, 960-966.
Mehta S, Yusuf S, Peters R, et al. - Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358, 527-533.
Ko D, Chiu M, Guo H, et al. - Pattern use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents. Am Heart J, 2009, 158, 592-598.
Spertus JA, Kettelkamp R, Vance C, et al. - Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006, 113, 2803-2809.
Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. - A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 29 patients at risk for coronary artery disease. Eur Heart J, 2006, 27, 2667-2674.
Collet JP, Aout M, Alantar A, et al. - Real-life management of dual antiplatelet therapy interruption: the REGINA survey. Arch Cardiovasc Dis, 2009, 102, 697-710.
Tantry US, Bliden KP, Gurbel PA. - Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol, 2005, 46, 1705-1709.
Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. - Aspirin «resistance» and the risk of cardiovascular morbidity : systematic review and meta analysis. Br Med J, 2008, 336, 195-198.
Sweeny JM, Gorog DA, Fuster V. - Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol, 2009, 6, 273-282.
Gorog DA, Sweeny JM, Fuster V. - Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artefact? Nat Rev Cardiol, 2009, 6, 365-373.
Sabatine MS, Cannon CP, Gibson GM, et al. - Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-clarity study. JAMA, 2005, 294, 1224-1232.
COMMIT (Clopidogrel and metoprolol in myocardial infarction trial) collaborative group. - Addition to clopidogrel to aspirin in 45 852 patients with acute myocardial infarction : randomised placebo-controlled trial. Lancet, 2005, 366, 1607-1621.
CURE Trial Investigators. - Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med, 2001, 345, 494-502.
Steinhubl SR, Berger PB, Mann JT 3rd, et al, CREDO Investigators. - Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial. JAMA, 2002, 288, 2411-2420.
Bhatt DL, Fox KA, Hacke W, et al. - CHARISMA Investigators. - Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354, 1706-1717.
Gillard M, Arnaud B, Cornily JC, et al.- Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized double-blind OCLA (Omeprazole CLopidogrel Aspirine) study. J Am Coll Cardiol, 2008, 51, 256-260.
Sibbing D, Kastrati A. - Risk of combining PPIs with thienopyridines: fact or fiction? Lancet, 2009, 34, 952-954.
Kastrati A, Mehilli J, Pache J, et al. - Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007, 356, 1030-1039.
Spaulding C, Daemen J, Boersma E, et al. - A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007, 356, 989-997. (Pubitemid 46376799)
Eisenstein EL, Anstrom KJ, Kong DF, et al. - Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 2007, 297, 159-168.
Nyssen A, Legrand V, Scheen AJ. - Rapport bénéfice-risque des endoprothèses coronaires pharmaco-actives. 1ère partie : analyse dans la population générale. Rev Med Liège, 2008, 63, 542-548.
Stone GW, Ellis SG, Colombo A, et al. - Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). Am J Cardiol, 2008, 102, 1017-1022.
Byrne RA, Schulz S, Mehilli J, et al, ISAR-SAFE Investigators. - Rationale and design of a randomized, double- blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J, 2009, 157, 620-624.
Schulz S, Schuster T, Mehilli J, et al. - Stent thrombosis after drug-eluting stent implantation: incidence, timing and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J, 2009, 30, 2714-2721.
Shin DH, Chae IH, Youn TJ, et al. - Reasonable duration of clopidogrel use after drug-eluting stent implantation in Korean patients. Am J Cardiol, 2009, 12, 1668-1673.
Iakovou I, Schmidt T, Bonizzoni E, et al. - Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005, 293, 2126-2130.
Park DW, Park SW, Park KH, et al. - Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long term follow-up. Am J Cardiol, 2006, 98, 352-356.
Kuchulakanti PK, Chu WW, Torguson R, et al. - Correlates and long term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation, 2006, 113, 1108-1113.
Airoldi F, Colombo A, Morici N, et al. - Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation, 2007, 116, 745-754.
Maeyns K, Legrand V, Piérard LA, Lancellotti P. - Antiagrégants : doit-on les arrêter avant un acte invasif ? Rev Med Liège, 2008, 63, 136-140.